Key Highlights

  • Revenue of USD 116.52 million compares with an estimate of USD 63.00 million and USD 21.0 million a year earlier.
  • Diluted EPS was USD 0.50 against an estimate of a USD 0.33 loss and a USD 0.08 loss last year.
  • Royalty Revenue was USD 87.52 million, including USD 77.4 million recognized from the USD 105.0 million Alexion settlement.
  • Cash, cash equivalents and marketable Debt securities were USD 555.7 million at September 30, against USD 610.8 million in December.

Xencor, Inc. (NASDAQ:XNCR) reported third quarter revenue of USD 116.52 million, against an estimate of USD 63.00 million and USD 20.999 million in the same quarter of 2025. Diluted EPS was USD 0.50, against an estimate of a USD 0.33 loss. A year earlier the company recorded a diluted loss of USD 0.08 per share.

Revenue

Royalties were USD 87.52 million against USD 21.0 million a year ago, and milestone revenue was USD 29.0 million with none in the prior-year quarter. The company recognized USD 83.5 million of Alexion Royalty revenue, against USD 18.7 million. Of that, USD 77.4 million came from the settlement signed on July 29, 2026, which resolved a dispute over U.S. royalties on Ultomiris.

Under the settlement the company is entitled to USD 105.0 million in two equal installments of USD 52.5 million. The first was received in August 2026, and the second is due within 14 days after the first anniversary of the agreement. Milestone revenue reflected, in part, a USD 25.0 million payment from Astellas, triggered when it started a Phase 3 trial of ASP2138 in August 2026. Nine-month revenue was USD 172.26 million against USD 97.34 million.

Net Income and Operating Costs

Operating income was USD 22.86 million, against an operating loss of USD 47.52 million a year earlier. Net Income attributable to the company was USD 39.44 million, against a net loss of USD 6.03 million.

Research and development expense was USD 84.30 million against USD 54.37 million, while general and administrative expense was USD 9.36 million against USD 14.15 million. Other income, net was USD 16.40 million against USD 41.49 million, with gains on Equity securities of USD 15.2 million against USD 44.2 million. For the nine months, the company reported a net loss of USD 111.2 million, or USD 1.47 per share, against USD 85.3 million, or USD 1.15 per share.

Cash and Pipeline Funding

Cash, cash equivalents and marketable debt securities were USD 555.7 million at September 30, against USD 610.8 million at December 31, 2025. Cash used in Operating Activities over the nine months was USD 120.6 million against USD 83.4 million, which the company tied to an increase in receivables related to the Alexion settlement and higher operating spending. Management said existing cash, marketable securities and certain potential milestone payments would fund operating expenses and Capital needs into 2029.

Pipeline work continues across oncology and autoimmune programs. For XmAb819 in clear cell renal cell carcinoma, the company selected the 400 mcg/kg intravenous dose as the proposed Phase 3 dose, citing five confirmed partial responses among 11 evaluable patients at the October 1, 2026 data cut. In July 2026 the FDA granted Fast Track Designation to XmAb541 for relapsed or refractory germ cell tumors.

Numbers in Context

Revenue of USD 116.52 million sits alongside net income of USD 39.44 million, Research and Development expense of USD 84.30 million and cash and securities of USD 555.7 million.

Management named several dated items. Initial plamotamab data in rheumatoid arthritis were accepted for presentation at a medical conference in November 2026. A blinded interim analysis of the XENITH-UC Phase 2b study of XmAb942 is planned around year end 2026, with the primary endpoint analysis in the second half of 2027. In the first half of 2027 the company plans to present further XmAb819 results and engage with the FDA on a potential Accelerated Approval pathway, and by the end of 2027 it plans to start a global Phase 3 study, subject to regulatory feedback.